The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Melanoma Genomics

Faculty of Medicine / Department of Clinical Sciences, Lund / Section I / Melanoma

Visiting address: Scheelevägen, Medicon Village, hus 404, Lund

Service point: 90

Melanoma Genomics' profile in Lund University Research portal

Description

Recently the treatment landscape of metastatic melanoma has changed dramatically with introduction of targeted therapy and novel immune checkpoint blockade agents. However, acquired resistance to targeted therapy and relatively low response rates to immune therapy poses a major problem. Thus, increased knowledge in melanoma biology and identification of novel therapeutic strategies is a necessity to further increase survival. We posit that using human tumor molecular data as a foundation for functional studies will lead us to novel insights about the fundamental biology of melanoma as well as provide us with inspiration for designing novel therapeutic strategies. Accordingly, our research program is focused on genomic tumor biology and the subsequent functional elucidation of biological mechanisms. We are also part of international melanoma consortia such as MELGEN (www.melgen.org) and GenoMEL (www.genomel.org).

Staff

H

  • Katja Harbst

    Research project participant

    katja [dot] harbst [at] med [dot] lu [dot] se

J

L

  • Martin Lauss

    Research project participant

    martin [dot] lauss [at] med [dot] lu [dot] se

  • Helena Liljedahl

    Research project participant

    helena [dot] liljedahl [at] med [dot] lu [dot] se

P

  • Bengt Phung

    Research project participant

    bengt [dot] phung [at] med [dot] lu [dot] se